ArticleBMC public health2026
HPV vaccine: the key to a powerful shield against cancer.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman papillomavirus (HPV) is a major global public health concern associated with multiple cancers. Despite the proven effectiveness of HPV vaccines, disparities in knowledge and vaccination uptake persist. This study aimed to assess HPV-related knowledge, awareness, and vaccination behaviors in a large population-based sample in Türkiye and to identify key determinants influencing vaccination.
methodsThis descriptive cross-sectional study included 12,093 individuals aged 18–49 from all seven geographical regions of Türkiye. Data were collected using a structured questionnaire assessing sociodemographic characteristics and HPV-related knowledge. Descriptive statistics, chi-square tests, and binary logistic regression analyses were performed using SPSS 25.0.
resultsWhile 73.4% of participants reported awareness of cervical cancer, knowledge regarding specific aspects of HPV vaccination, such as dosage schedule (44.1%) and cost (41.0%), was lower, and 24.5% reported no knowledge of the vaccine. Multivariate logistic regression analysis identified several significant predictors of vaccination, including history of sexually transmitted infections (OR = 32.45), prior HPV knowledge (OR = 19.10), support for national vaccination programs (OR = 6.95), and higher income (OR = 5.74) (p < 0.05). Healthcare engagement factors such as Pap smear testing were also positively associated with vaccination (OR = 3.12).
conclusionAlthough general awareness of HPV-related diseases is relatively high, gaps remain in practical knowledge and vaccination uptake. Addressing these gaps requires targeted educational interventions, improved access to accurate information, and policies aimed at reducing socioeconomic barriers. Integrating HPV vaccination into national immunization programs may enhance equitable access and improve public health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.